JP7904995B2 - Nrf2活性化作用を有する含窒素複素環化合物の結晶 - Google Patents
Nrf2活性化作用を有する含窒素複素環化合物の結晶Info
- Publication number
- JP7904995B2 JP7904995B2 JP2025528066A JP2025528066A JP7904995B2 JP 7904995 B2 JP7904995 B2 JP 7904995B2 JP 2025528066 A JP2025528066 A JP 2025528066A JP 2025528066 A JP2025528066 A JP 2025528066A JP 7904995 B2 JP7904995 B2 JP 7904995B2
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- powder
- diffraction
- ray diffraction
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023100075 | 2023-06-19 | ||
| JP2023100075 | 2023-06-19 | ||
| PCT/JP2024/022040 WO2024262491A1 (ja) | 2023-06-19 | 2024-06-18 | Nrf2活性化作用を有する含窒素複素環化合物の結晶 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2024262491A1 JPWO2024262491A1 (cg-RX-API-DMAC7.html) | 2024-12-26 |
| JPWO2024262491A5 JPWO2024262491A5 (cg-RX-API-DMAC7.html) | 2026-06-11 |
| JP7904995B2 true JP7904995B2 (ja) | 2026-08-13 |
Family
ID=93935419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025528066A Active JP7904995B2 (ja) | 2023-06-19 | 2024-06-18 | Nrf2活性化作用を有する含窒素複素環化合物の結晶 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4696692A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7904995B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20260023529A (cg-RX-API-DMAC7.html) |
| CN (1) | CN121152792A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2024314540A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL324833A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025014082A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202504613A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024262491A1 (cg-RX-API-DMAC7.html) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018181345A1 (ja) | 2017-03-28 | 2018-10-04 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2020241853A1 (ja) | 2019-05-31 | 2020-12-03 | 宇部興産株式会社 | ベンゾトリアゾール誘導体 |
| JP2022520442A (ja) | 2019-02-15 | 2022-03-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Nrf2活性剤としてのヒドロキシピリドキシアゼピン |
| CN114507181A (zh) | 2020-11-17 | 2022-05-17 | 中国医学科学院药物研究所 | 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用 |
| JP2023038270A (ja) | 2018-08-20 | 2023-03-16 | ヤンセン ファーマシューティカ エヌ.ベー. | KEAP1-Nrf2タンパク質-タンパク質相互作用の阻害剤 |
| JP2023524207A (ja) | 2020-04-22 | 2023-06-09 | シーフォーエックス・ディスカバリー・リミテッド | Nrf2活性化剤としてのテトラヒドロイソキノリン化合物 |
| WO2023132369A1 (ja) | 2022-01-07 | 2023-07-13 | 中外製薬株式会社 | Nrf2活性化作用を有する含窒素複素環化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
| US20190380992A1 (en) | 2014-12-04 | 2019-12-19 | Biogen Ma Inc. | Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate |
-
2024
- 2024-06-18 EP EP24825892.3A patent/EP4696692A1/en active Pending
- 2024-06-18 AU AU2024314540A patent/AU2024314540A1/en active Pending
- 2024-06-18 TW TW113122470A patent/TW202504613A/zh unknown
- 2024-06-18 KR KR1020257042624A patent/KR20260023529A/ko active Pending
- 2024-06-18 CN CN202480033461.0A patent/CN121152792A/zh active Pending
- 2024-06-18 IL IL324833A patent/IL324833A/en unknown
- 2024-06-18 WO PCT/JP2024/022040 patent/WO2024262491A1/ja not_active Ceased
- 2024-06-18 JP JP2025528066A patent/JP7904995B2/ja active Active
-
2025
- 2025-11-25 MX MX2025014082A patent/MX2025014082A/es unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018181345A1 (ja) | 2017-03-28 | 2018-10-04 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2023038270A (ja) | 2018-08-20 | 2023-03-16 | ヤンセン ファーマシューティカ エヌ.ベー. | KEAP1-Nrf2タンパク質-タンパク質相互作用の阻害剤 |
| JP2022520442A (ja) | 2019-02-15 | 2022-03-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Nrf2活性剤としてのヒドロキシピリドキシアゼピン |
| WO2020241853A1 (ja) | 2019-05-31 | 2020-12-03 | 宇部興産株式会社 | ベンゾトリアゾール誘導体 |
| JP2023524207A (ja) | 2020-04-22 | 2023-06-09 | シーフォーエックス・ディスカバリー・リミテッド | Nrf2活性化剤としてのテトラヒドロイソキノリン化合物 |
| CN114507181A (zh) | 2020-11-17 | 2022-05-17 | 中国医学科学院药物研究所 | 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用 |
| WO2023132369A1 (ja) | 2022-01-07 | 2023-07-13 | 中外製薬株式会社 | Nrf2活性化作用を有する含窒素複素環化合物 |
Non-Patent Citations (1)
| Title |
|---|
| NARAYANAN, Dilip et al.,Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery,J. Med. Chem.,2022年,Vol.65,pp.14481-14526 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202504613A (zh) | 2025-02-01 |
| IL324833A (en) | 2026-01-01 |
| MX2025014082A (es) | 2026-01-07 |
| AU2024314540A1 (en) | 2025-11-27 |
| KR20260023529A (ko) | 2026-02-20 |
| EP4696692A1 (en) | 2026-02-18 |
| JPWO2024262491A1 (cg-RX-API-DMAC7.html) | 2024-12-26 |
| CN121152792A (zh) | 2025-12-16 |
| WO2024262491A1 (ja) | 2024-12-26 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260602 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260602 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20260602 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20260602 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260630 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260728 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260731 |